Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Vyndaqel, Vyndamax
Tafamidis is an oral medication used to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare, life-threatening disease caused by the buildup of misfolded transthyretin protein in the heart. It belongs to a class of drugs known as transthyretin stabilizers. Tafamidis works by binding to and stabilizing transthyretin tetramers, preventing their dissociation into monomers, which are the building blocks of amyloid fibrils. This stabilization reduces amyloid deposition in the heart, improving cardiac function and symptoms.
For the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
Outcome:
Significant increase in tafamidis exposure
Mechanism:
Inhibition of CYP2C9 and CYP3A4
Outcome:
Increased midazolam exposure
Mechanism:
Inhibition of CYP3A4
Outcome:
Slight increase in digoxin exposure
Mechanism:
Inhibition of P-gp
Most likely new formulation: Controlled-release formulation to improve patient compliance (Year: 2026, 70% confidence)
Based on increasing clinical trial data and positive patient outcomes, there is a high likelihood (>80%) of continued regulatory support for tafamidis in ATTR-CM and potential expansion to other transthyretin-related amyloidoses.
Transthyretin Stabilizer
Benzoxazole Derivative